chlormadinone and ethinylestradiol

G03AA15

Forms & Strengths

Adult Dosing

Oral: 1 tablet daily for 21 consecutive days, followed by a 7-day pill-free interval
Start on day 1 of the natural menstrual cycle

Pediatric Dosing

Indications

Mechanism of Action

Combination of an antiandrogenic progestin (chlormadinone acetate) and an estrogen (ethinylestradiol)
Inhibits ovulation primarily via suppression of hypothalamic gonadotropins (LH and FSH)
Alters cervical mucus viscosity to impede sperm penetration and changes endometrium to inhibit implantation

Contraindications

Presence or risk of venous thromboembolism (VTE)
Presence or risk of arterial thromboembolism (ATE)
Known or suspected sex-steroid sensitive malignancies
Severe hepatic disease or tumors
Undiagnosed abnormal vaginal bleeding
Hypersensitivity to active substances or excipients
Concomitant use with hepatitis C virus (HCV) drug combinations containing ombitasvir/paritaprevir/ritonavir and dasabuvir

Adverse Reactions

Common: Headache, nausea, breast tenderness, breakthrough bleeding, spotting
Less common: Libido changes, depressed mood, migraine, vomiting, acne, dysmenorrhea
Serious: Venous and arterial thromboembolism, myocardial infarction, stroke, hepatic adenomas, hypertension

Drug Interactions

CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) decrease contraceptive efficacy
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase plasma concentrations of the hormones
Antidiabetic agents: Combined oral contraceptives may affect glucose tolerance; dosage adjustments of insulin or oral antidiabetics may be required
Lamotrigine: Estrogen-containing contraceptives decrease lamotrigine plasma concentrations, risking loss of seizure control

Curated Content: Needs Vetting Before Put to Clinical Use